Comments
Elbrit Life Sciences is not intimidated by its late entry into Indian pharmaceutical industry.
It is never too late, says Elbrit chief Executive Prakash KS, adding that the company would make generic drugs in the cardiac and diabetic segments to start with.
With United Kingdom-based science- and-research-to-education group investing in Elbrit, the fledgeling company expects to start with about 30 products, and the portfolio will be expanded gradually, he says. The generic medicines would be made by third-party plants based in Himachal Pradesh and Assam.
Generic drugs are medicines that are similar to an innovative drug and have the same therapeutic effect.
Details on the UK business group investing in Elbrit and other financials were not divulged by the company. But in-step with the prevailing concerns of the industry, he says, the company’s priority is to have the medicines made inline with Food and Drug Administration rules.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.